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Genome-wide association studies (GWAS) have identified specific 
common  genetic  variants  within  a  region  on  the  long  arm  of 
chromosome 15 (15q25) as risk factors for lung cancer (1–3) and 
other smoking-related health outcomes, such as chronic obstruc-
tive pulmonary disease (4,5), peripheral arterial disease (3,6), low 
birth weight in offspring (7), and lower body mass index (8). This 
region contains the a5, a3, and b4 nicotinic acetylcholine receptor 
subunit  gene  cluster,  CHRNA5-CHRNA3-CHRNB4  (CHRNA5-
A3-B4);  although  most  studies  to  date  have  focused  on  the 
rs16969968  and  rs1051730  single-nucleotide  polymorphisms 
(SNPs) within this gene cluster, there is emerging evidence that 
other SNPs within this region are also associated with smoking 
behavior (9). A few studies have suggested that rs16969968 and 
rs1051730 SNPs do not relate to smoking history (2,10), but most 
have found them to be associated with a variety of smoking-related 
phenotypes, including tobacco dependence, heaviness of smoking 
(ie, number of cigarettes per day), risk of relapse after quitting 
smoking, age at initiation of smoking, and subjective response to 
the first cigarette smoked (1,3,7,9,11–22).
The first published study that investigated this region in rela-
tion to cigarette smoking identified the rs16969968 SNP (23), and 
this  was  subsequently  confirmed  at  a  genome-wide  statistically 
significant threshold (24). A recent study showed that the minor 
allele  of  the  rs16969968  missense  polymorphism,  D398N,  in 
CHRNA5 was associated with a reduced response to a nicotinic 
agonist in vitro (25) and may therefore be the functional variant 
responsible  for  the  association  with  smoking  quantity.  The 
rs1051730 SNP is located within the CHRNA3 gene, in a linkage 
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smoking behavior, which may not fully capture interindividual variation in tobacco exposure.
  Methods  We investigated the association of rs1051730 and rs16969968 genotype (referred to as rs1051730–rs16969968, 
because these are in perfect linkage disequilibrium and interchangeable) with both self-reported daily cigarette 
consumption and biochemically measured plasma or serum cotinine levels among cigarette smokers. Summary 
estimates and descriptive statistical data for 12 364 subjects were obtained from six independent studies, and 
2932 smokers were included in the analyses. Linear regression was used to calculate the per-allele association 
of rs1051730–rs16969968 genotype with cigarette consumption and cotinine levels in current smokers for each 
study. Meta-analysis of per-allele associations was conducted using a random effects method. The likely result-
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cotinine levels (mean increase in unadjusted cotinine levels per allele = 138.72 nmol/L, 95% CI = 97.91 to 179.53 
nmol/L, P = 2.71 × 10211). The increase in cotinine levels indicated an increased risk of lung cancer with each 
additional copy of the rs1051730–rs16969968 risk allele (per-allele odds ratio = 1.31, 95% CI = 1.21 to 1.42).
  Conclusions  Our data show a stronger association of rs1051730–rs16969968 genotype with objective measures of tobacco 
exposure compared with self-reported cigarette consumption. The association of these variants with lung cancer 
risk is likely to be mediated largely, if not wholly, via tobacco exposure.
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disequilibrium (LD) block within CHRNA5-A3-B4, and has also 
been shown to be associated with heaviness of smoking (3). This 
SNP is in perfect linkage disequilibrium with rs16969968 in sam-
ples of European ancestry (LD decay [D′] = 1.0, LD correlation 
coefficient [R
2] = 1.0), and the two SNPs are commonly treated 
interchangeably (hereafter referred to as rs1051730–rs16969968). 
Across these studies, minor allele (rs1051730 T, rs16969968 A) 
carriers show increased risk of heavier smoking, as well as lung 
cancer and other health-related outcomes, compared with wild-type 
(rs1051730 C, rs16969968 G) homozygotes.
However, these studies typically rely on self-reported measures of 
smoking behavior, which do not fully capture interindividual varia-
tion in tobacco exposure (26). Two small studies have reported on 
the association of rs1051730–rs16969968 with heaviness of smoking 
among current smokers, measured by self-reported daily cigarette 
consumption and by levels of cotinine and other nicotine metabolites 
in serum (27,28). In one study, several nicotine metabolites in the 
urine were used to produce an index of nicotine equivalents (28). It 
showed that the risk alleles for lung cancer were associated with 
higher urinary nicotine equivalents among smokers, and this associ-
ation  remained  after  adjustment  for  self-reported  daily  cigarette 
consumption. This suggests that other aspects of smoking behavior 
that influence exposure, such as depth of inhalation, are associated 
with chromosome 15 risk alleles for lung cancer.
Misreporting of smoking behavior by smokers (eg, reporting 
that they smoke fewer cigarettes than they actually do) will also 
reduce the reliability of self-reported measures as an index of expo-
sure. Therefore, the use of self-report measures of smoking behav-
ior  could  lead  to  relationships  between  risk  alleles  and  disease 
outcomes  such  as  lung  cancer,  apparently  independently  of 
smoking intensity. Consequently, this would imply a direct associ-
ation of genotype with risk of disease outcomes, when, in fact, the 
association may be entirely because of tobacco exposure. If this is 
the case, the CHRNA5-A3-B4 SNPs should be more strongly 
associated with objective measures of tobacco exposure than with 
self-report  measures.  This  prediction  is  supported  by  another 
small  genetic  association  study  (27),  which  investigated  serum 
cotinine levels and self-reported smoking, and showed a consider-
ably stronger association with the objective measures of exposure 
(ie, cotinine levels).
Two  previous  studies  (27,28)  that  examined  the  association 
between CHRNA5-A3-B4 SNPs and both self-reported and objec-
tive measures of tobacco exposure were small. In this study, we 
extended this preliminary work by conducting a much larger col-
laborative investigation. We tested the association of rs1051730–
rs16969968 with both self-reported daily cigarette consumption 
and cotinine levels, which allowed us to estimate the extent to 
which  the  association  of  these  SNPs  with  smoking  behavior   
may have been underestimated, and thus the smoking-mediated 
influence  of  these  SNPs  on  lung  cancer  and  other  conditions 
underappreciated.
Materials and Methods
Study Population
Data  on  self-reported  smoking  status  (never  smoker,  former 
smoker, and current smoker), genotype (rs16969968 or rs1051730), 
and cotinine levels determined in blood (plasma or serum), as well 
as  cigarette  consumption  (cigarettes  per  day)  among  current 
smokers,  were  available  from  participants  of  self-reported 
European  ancestry  in  six  independent  studies  (British  Regional 
Heart Study [BRHS], n = 385 subjects; British Women’s Heart 
and  Health  Study  [BWHHS],  n  =  400  subjects;  European 
Prospective  Investigation  into  Cancer  and  Nutrition  [EPIC],   
n = 759 subjects; Midspan, n = 499 subjects; Patch II, n = 451 sub-
jects; Patch in Practice [PiP], n = 438 subjects) that contributed to 
this  analysis  (2,29–40).  All  studies  received  appropriate  ethics 
approval, and informed consent was obtained from each participant. 
These studies are described in detail in Supplementary Methods 
(available online).
The data from the EPIC study were drawn from a case–control 
lung cancer study nested within the EPIC cohort. Blood and ques-
tionnaire data on self-reported smoking behavior were collected in 
a prospective manner as part of the recruitment procedure and 
before cancer diagnosis in case subjects (41). However, cotinine 
levels and self-reported cigarette consumption in current smokers 
differed between case subjects (EPIC Case) and control subjects 
(EPIC Control). Mean cotinine levels were higher in the EPIC   
CONTEXT AND CAVEATS
Prior knowledge
Two interchangeable single-nucleotide polymorphisms, rs1051730 
and rs16969968, are associated with heaviness of smoking, risk for 
lung cancer, and other smoking-related health outcomes. Previous 
studies have mostly relied on retrospective self-reported smoking 
behavior, which may have produced underestimated associations 
and masked the contribution of smoking to the observed associa-
tion of these polymorphisms with lung cancer and other health 
outcomes.
Study design
Data from six independent studies were used to assess associa-
tions  of  rs1051730  and  rs16969968  genotype  (referred  to  as 
rs1051730–rs16969968) with self-reported daily cigarette consump-
tion and plasma or serum cotinine levels among cigarette smokers, 
and meta-analysis of per-allele effects was conducted. The likely 
resulting association between genotype and lung cancer risk was 
also assessed.
Contribution
Associations  of  rs1051730–rs16969968  risk  allele  with  increased 
self-reported cigarette consumption per day and increased cotinine 
levels were observed; however, the association with cotinine level 
was much stronger. This increase in cotinine levels indicated an 
increased risk of lung cancer (per-allele odds ratio = 1.31).
Implication
The association of rs1051730–rs16969968 genotype with lung can-
cer risk is mediated to a large extent, if not completely, by tobacco 
exposure.
Limitation
Analysis was based on current smoking status and not on lifetime 
exposure and also did not adjust for factors known to influence 
nicotine metabolism.
From the Editors
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Case subsample (1391 nmol/L, SD = 588 nmol/L) than the EPIC 
Control subsample (1006 nmol/L, SD = 589 nmol/L) even after 
adjustment for cigarette consumption (two-sided Kruskal–Wallis 
P < .001), indicating possible differences in smoking behavior 
(eg, depth of inhalation). This difference at baseline may have 
contributed to the likelihood of a subsequent lung cancer diagnosis. 
Therefore, the EPIC case subjects and control subjects were 
analyzed and presented separately in this study.
Statistical Analysis
In each contributing study, linear regression was used to calculate 
per-allele associations of rs1051730–rs16969968 genotype on daily 
cigarette  consumption  (cigarettes  per  day)  and  cotinine  levels 
(nmol/L) in current smokers. Analyses were conducted for both 
unadjusted and adjusted for cotinine levels (in the case of associa-
tions of genotype with daily cigarette consumption) and cigarette 
consumption (in the case of associations of genotype with cotinine 
levels). In the Midspan Family Study, which is one of the Midspan 
studies  (see  Supplementary  Methods,  available  online),  within-
family clustering was adjusted for by including a family-level ran-
dom  intercept  (42).  We  assumed  an  additive  model  of  genetic 
action, and a linear relationship between cigarette consumption 
and cotinine level, consistent with previous reports (3,43). The 
rs1051730 and rs16969968 variants are in perfect linkage disequi-
librium in HapMap3 samples of European ancestry (D′ = 1.0, R
2 = 
1.0) (http://hapmap.ncbi.nlm.nih.gov/), and therefore,  these  in-
terchangeable SNPs were considered as a single marker in these 
analyses. These per-allele associations were pooled using a random 
effects  method  (44).  Random  effects  models  are  typically  more 
conservative than fixed-effects models, although in the absence of 
substantial  between-study  heterogeneity,  the  two  methods  gen-
erate similar results and generate identical results where there is 
perfect homogeneity. The I
2 statistic was used to estimate the per-
centage  of  total  variation  in  study  estimates  resulting  from 
between-study heterogeneity. Conventionally, I
2 values less than 
25% are considered low and unlikely to represent important hetero-
geneity (45). The Cochran Q test was used to evaluate the statis-
tical evidence for between-study heterogeneity.
To assess the congruence of our results with odds ratios (ORs) 
for lung cancer reported for rs1051730–rs16969968 genotype (1), 
data were used from a large case–control study that assessed the 
relationship between serum cotinine levels and lung cancer (46). 
This study reported odds ratios and 95% confidence intervals (CIs) 
for eight separate cotinine intervals with reference to the lowest 
cotinine range, produced using conditional logistic regression 
with adjustment for sex, year of birth, time of enrollment, and 
geographical region, and with adjustment for measurement error 
using repeated cotinine measurements on a subset of samples. 
These eight odds ratios and confidence intervals were abstracted, 
together with the midpoint of each cotinine interval, converted   
to  nmol/L,  with  the  midpoint  of  the  highest  interval  taken  as   
400 ng/mL as in the original report. Odds ratios and their confi-
dence intervals were logarithmically transformed so that log odds 
ratios and their standard errors were calculated. The association 
between  cotinine  levels  and  lung  cancer  risk  is  shown  in 
Supplementary Figure 1 (available online). Weighted least squares 
regression was then carried out on log odds ratios, weighted by the 
inverse of the standard error squared, with the intercept forced to be 
0 to represent the odds ratio of 1 for the lowest cotinine interval. 
The resulting regression coefficient was then multiplied by the 
per-allele increase in cotinine estimated from this study and con-
verted to an expected odds ratio for lung cancer risk associated 
with each additional copy of the rs1051730–rs16969968 risk allele. 
Lower and upper limits of the confidence interval from the per-
allele increase were also calculated in the same way.
All analyses were conducted with Stata software (version 11.2; 
StataCorp, College Station TX). All statistical tests were two-sided, 
except where stated, and all P values of .05 or less were considered 
statistically significant.
Results
Characteristics of Participants
A total of 12 364 participants of self-reported European ancestry, 
with  complete  smoking  status  (including  cigarette  consumption 
among current smokers), cotinine levels, and genotype data, were 
available across six studies (see Table 1). Participants were classi-
fied as never smokers (n = 4771), former smokers (n = 4661), and 
current smokers (n = 2932) based on their self-reported smoking 
behavior (see Table 2).
Smoking Status, Genotype, and Cotinine Level
Cotinine levels confirmed the classification of participants as non-
smokers  (ie,  never  smokers  and  former  smokers)  and  current 
smokers (Table 2), based on conventional indicative cotinine levels 
among nonsmokers and current smokers (never smokers and former 
smokers, approximately 5 nmol/L; current smokers, >85 nmol/L) 
(47). Across all six studies, median cotinine levels for nonsmokers 
were 3.40 nmol/L or lower (ranging from 0.57 to 3.40 nmol/L), 
whereas  median  cotinine  levels  in  current  smokers  were  968.5 
nmol/L  or  higher  (ranging  from  968.5  to  1535.0  nmol/L).  As 
described  previously,  cotinine  levels  in  current  smokers  in  the 
EPIC study differed between case subjects and control subjects and 
were therefore considered separately.
Our  analysis  was  based  on  current  smokers  to  ascertain  the   
relationship  between  rs1051730–rs16969968  genotype  and  both 
daily cigarette consumption and cotinine levels. Median cotinine 
levels in current smokers increased with each copy of the minor allele 
(rs1051730 T, rs16969968 A), typically by about 140 nmol/L (range 
= 45–255 nmol/L) (Table 2). Individual study associations between 
genotype and both daily cigarette consumption and cotinine levels 
are reported in Supplementary Table 1 (available online).
Association of rs1051730–rs16969968 Genotype With Daily 
Cigarette Consumption
Meta-analysis  of  the  per-allele  association  of  rs1051730–
rs16969968 genotype on unadjusted self-reported daily cigarette 
consumption among current smokers indicated strong evidence of 
association (Figure 1). Pooling the six studies within a random 
effects framework indicated that the risk allele was associated with 
increased self-reported cigarette consumption (mean increase in 
number of cigarettes per day per allele = 1.0 cigarette, 95% CI = 0.57 
to 1.43 cigarettes, P = 5.22 × 10
26). The between-study heteroge-
neity was low and not statistically significant (I
2 = 0%, Pheterogeneity = .72). jnci.oxfordjournals.org    JNCI | Review 743
After adjustment for cotinine levels, the per-allele estimate was 
reduced by 50% (mean increase in number of cigarettes per day 
per allele = 0.45, 95% CI = 0.05 to 0.86 cigarettes, P = .029). 
Between-study heterogeneity remained low and was not statistically 
significant (I
2 = 0%, Pheterogeneity = .51). Weak evidence for a difference 
between the estimates for the unadjusted and adjusted analyses was 
observed (P = .07) (not shown in the figure).
Association of rs1051730-rs16969968 With Cotinine Levels
Meta-analysis  of  the  per-allele  association  of  rs1051730–
rs16969968 genotype on unadjusted cotinine levels among current 
smokers  indicated  strong  evidence  of  association  (Figure  2). 
Pooling the six studies within a random effects framework indi-
cated that the risk allele was associated with increased cotinine 
levels (mean increase in cotinine levels per allele = 138.72 nmol/L, 
95% CI = 97.91 to 179.53 nmol/L, P = 2.71 × 10
211). The between-
study heterogeneity was low and not statistically significant (I
2 = 23%, 
Pheterogeneity = .26). Following adjustment for self-reported cigarette 
consumption, the per-allele estimate was reduced by only 18% 
(mean increase in cotinine levels per allele = 113.76 nmol/L, 95% 
CI = 76.88 to 150.64 nmol/L, P = 1.49 × 10
29). Between-study 
heterogeneity remained low and was not statistically significant 
(I
2 = 16%, Pheterogeneity = .31). No evidence for a difference between 
the estimates for the unadjusted and adjusted analyses was observed 
(P = .37) (not shown in the figure).
Association of rs1051730–rs16969968 Genotype With Lung 
Cancer Risk
To  estimate  the  extent  to  which  the  association  of  rs1051730–
rs16969968 genotype with lung cancer is mediated via smoking, 
we applied the effect size we observed for the association with 
cotinine levels to published data on the association between cotinine 
levels and lung cancer risk. Applying weighted least squares regression 
to the log odds ratios presented by Boffetta et al. (46) produced a 
regression coefficient of 0.001945 per nmol/L of serum cotinine 
for the association between cotinine levels and lung cancer risk 
(Supplementary  Figure  1,  available  online).  Thus,  the  observed 
per-allele  increase  in  cotinine  levels  of  138.72  nmol/L  (95%   
CI = 97.91 to 179.53) would indicate an increased risk of lung 
cancer  with  each  additional  copy  of  the  rs1051730–rs16969968 
risk allele (per-allele OR = 1.31, 95% CI = 1.21 to 1.42). This 
corresponds closely with published data for the association between 
rs1051730–rs16969968 genotype and lung cancer risk, where an 
odds ratio of 1.32 has been reported (1).
Sample Size Calculation for GWAS
We next assessed the implications of the observed stronger associ-
ation  of  rs1051730–rs16969968  genotype  with  cotinine  levels, 
compared with self-reported daily cigarette consumption, for the 
design of future GWAS. The association of rs1051730–rs16969968 
with self-reported daily cigarette consumption and cotinine levels 
indicated by our results suggests that a GWAS would require   
a  sample size in excess of 7000 to detect an association of the 
rs1051730–rs16969968 variant with self-reported daily cigarette 
consumption, but a sample size of only 1800–1900 to detect an 
association with cotinine levels, assuming an additive model for the 
genetic association, a minor allele frequency of 0.35, an alpha level 
of 5 × 10
28, and a required power of at least 80%. In addition, a 
recall-by-genotype design, where rs1051730–rs16969968 homozy-
gotes are preselected, would require a sample size of only 200 to 
detect this association with cotinine levels, with an alpha level of 
0.05, and a required power of at least 80%.
Discussion
Our data show that rs1051730–rs16969968 genotype is strongly 
associated with tobacco exposure measured objectively via cotinine 
levels and that this association is robust even after adjustment for 
self-reported cigarette consumption. We used the per-allele asso-
ciation  of  genotype  on  cotinine  levels  to  estimate  the  association 
between  rs1051730–rs16969968  genotype  and  lung  cancer  risk, 
using published data on the association between cotinine levels and 
Table 1. Characteristics of participants by study*
Characteristic
Study
BRHS  
(n = 3613)
BWHHS  
(n = 3684)
EPIC Case†  
(n = 758)
EPIC Control†  
(n = 1548)
Midspan  
(n = 1872)
Patch II  
(n = 451) PiP (n = 438)
Sex, No. (%)            
  Male 3613 (100%) — 687 (64%) 948 (61%) 855 (46%) 166 (37%) 221 (51%)
  Female — 3684 (100%) 71 (36%) 600 (39%) 1017 (54%) 285 (63%) 217 (49%)
Age, mean (range), y 69 (58–81) 69 (59–80) 58 (34–78) 58 (35–79) 45 (30–59) 51 (33–73) 44 (19–78)
Genotype‡ rs1051730 rs1051730 rs1699698 rs1699698 rs1051730 rs1051730 rs1051730
Biological material Serum Serum Serum Serum Serum Plasma Plasma
*  Data on genotype (rs16969968 or rs1051730), smoking status (never smoker, former smoker, and current smoker), and cotinine levels determined in blood 
(plasma or serum), as well as cigarette consumption (cigarette per day) among current smokers, in participants of European ancestry were available from six 
independent studies (BRHS = British Regional Heart Study; BWHHS = British Women’s Heart and Health Study; EPIC = European Prospective Investigation into 
Cancer and Nutrition; PiP = Patch in Practice).
†  Cotinine levels and self-reported cigarette consumption differed in current smoker case subjects (EPIC Case) and control subjects (EPIC Control). Mean cotinine 
levels were higher in the EPIC Case subsample (1391 nmol/L, SD = 588) than the EPIC Control subsample (1006 nmol/L, SD = 589) even after adjustment for 
cigarette consumption (Kruskal–Wallis P < .001, two-sided), indicating possible differences in smoking behavior (eg, depth of inhalation). This difference at 
baseline may have contributed to the likelihood of a subsequent lung cancer diagnosis. Therefore, the EPIC case subjects and control subjects were analyzed  
and presented separately in this study.
‡  Genotype: rs1051730 (wild-type allele C, risk allele T); rs16969968 (wild-type allele G, risk allele A).744   Review | JNCI  Vol. 104, Issue 10  |  May 16, 2012
T
a
b
l
e
 
2
.
 
C
o
t
i
n
i
n
e
 
l
e
v
e
l
s
 
b
y
 
s
m
o
k
i
n
g
 
b
e
h
a
v
i
o
r
 
a
n
d
 
g
e
n
o
t
y
p
e
 
i
n
 
c
u
r
r
e
n
t
 
s
m
o
k
e
r
s
*
S
m
o
k
i
n
g
 
 
b
e
h
a
v
i
o
r
 
 
o
r
 
N
o
.
 
o
f
 
 
r
i
s
k
 
a
l
l
e
l
e
s
 
 
i
n
 
c
u
r
r
e
n
t
 
 
s
m
o
k
e
r
s
†
B
R
H
S
B
W
H
H
S
E
P
I
C
 
C
a
s
e
‡
E
P
I
C
 
C
o
n
t
r
o
l
‡
M
i
d
s
p
a
n
P
a
t
c
h
 
I
I
P
i
P
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
P
a
r
t
i
c
i
p
a
n
t
s
,
 
 
N
o
.
 
(
%
)
C
o
t
i
n
i
n
e
,
 
 
m
e
d
i
a
n
 
(
I
Q
R
)
,
 
 
n
m
o
l
/
L
S
m
o
k
i
n
g
 
 
s
t
a
t
u
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N
e
v
e
r
 
 
 
 
S
m
o
k
e
r
s
1
0
6
6
 
(
3
0
%
)
0
.
7
9
 
 
(
0
.
2
8
–
2
.
1
6
)
2
0
8
1
 
(
5
6
%
)
0
.
5
7
 
 
(
0
.
2
8
–
1
.
3
1
)
9
2
 
(
1
2
%
)
1
.
5
8
 
 
(
0
.
2
1
–
3
.
0
0
)
6
8
5
 
(
4
4
%
)
1
.
7
6
 
 
(
0
.
6
0
–
4
.
0
7
)
8
4
7
 
(
4
5
%
)
2
.
8
4
 
 
(
1
.
7
0
–
5
.
6
7
)
0
 
(
0
%
)
 
0
 
(
0
%
)
 
F
o
r
m
e
r
 
 
 
 
S
m
o
k
e
r
s
2
1
6
2
 
(
6
0
%
)
1
.
1
3
 
 
(
0
.
2
8
–
4
.
3
1
)
1
2
0
3
 
(
3
3
%
)
0
.
8
0
 
 
(
0
.
2
8
–
2
.
2
2
)
2
2
1
 
(
2
9
%
)
2
.
2
5
 
 
(
0
.
9
2
–
5
.
0
1
)
5
4
9
 
(
3
5
%
)
1
.
8
8
 
 
(
0
.
8
2
–
4
.
4
9
)
5
2
6
 
(
2
8
%
)
3
.
4
0
 
 
(
1
.
7
0
–
9
.
0
8
)
0
 
(
0
%
)
 
0
 
(
0
%
)
 
C
u
r
r
e
n
t
 
 
 
 
S
m
o
k
e
r
s
3
8
5
 
(
1
0
%
)
1
3
3
0
.
2
 
 
(
7
9
1
.
1
–
1
8
1
4
.
2
)
4
0
0
 
(
1
1
%
)
1
2
1
9
.
5
 
 
(
7
4
5
.
8
–
1
7
8
6
.
4
)
4
4
5
 
(
5
9
%
)
1
4
0
1
.
5
 
 
(
1
0
3
6
.
4
–
1
7
6
7
.
7
)
3
1
4
 
(
2
0
%
)
9
6
8
.
5
 
 
(
5
0
7
.
5
–
1
3
8
6
.
8
)
4
9
9
 
(
2
7
%
)
1
4
4
4
.
2
 
 
(
8
0
0
.
2
–
1
8
9
6
.
0
)
4
5
1
 
(
1
0
0
%
)
1
5
3
5
.
0
 
 
(
1
1
6
7
.
6
–
1
9
4
5
.
9
)
4
3
8
 
(
1
0
0
%
)
1
5
2
6
.
2
 
 
(
1
1
0
2
.
2
–
2
0
4
2
.
4
)
N
u
m
b
e
r
 
o
f
 
 
r
i
s
k
 
a
l
l
e
l
e
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
1
7
5
 
(
4
5
%
)
1
1
7
1
.
8
 
 
(
6
7
5
.
3
–
1
7
3
5
.
4
)
1
7
1
 
(
4
3
%
)
1
0
9
0
 
 
(
6
4
5
.
8
–
1
6
1
2
.
6
)
1
5
1
 
(
3
4
%
)
1
2
7
2
.
2
 
 
(
9
3
6
.
2
–
1
6
4
4
.
8
)
1
2
9
 
(
4
1
%
)
9
3
0
.
1
7
 
 
(
4
9
1
.
3
–
1
3
1
0
)
2
4
2
 
(
4
8
%
)
1
3
8
3
.
8
 
 
(
7
6
4
.
5
–
1
8
0
9
.
3
)
1
9
0
 
(
4
2
%
)
1
4
6
4
 
 
(
1
0
9
0
.
3
–
1
8
7
9
.
1
)
1
9
1
 
(
4
4
%
)
1
4
2
1
.
7
 
 
(
1
0
4
4
.
6
–
1
9
4
4
.
3
)
 
1
1
7
1
 
(
4
5
%
)
1
3
8
5
.
8
 
 
(
8
1
8
.
3
–
1
9
5
6
.
1
)
1
8
5
 
(
4
6
%
)
1
2
6
4
.
7
 
 
(
7
9
0
.
7
–
1
9
0
2
.
2
)
2
0
3
 
(
4
6
%
)
1
4
9
8
.
8
 
 
(
1
0
5
9
.
1
–
1
8
0
4
.
1
)
1
4
5
 
(
4
6
%
)
9
9
1
.
8
 
 
(
5
4
8
.
7
–
1
3
8
6
.
8
)
2
0
1
 
(
4
1
%
)
1
4
8
4
.
5
 
 
(
8
4
0
.
4
–
1
9
4
2
.
5
)
1
9
8
 
(
4
4
%
)
1
5
3
9
.
9
 
 
(
1
2
0
7
.
4
–
1
9
0
4
.
3
)
1
9
8
 
(
4
5
%
)
1
5
5
9
.
4
 
 
(
1
1
2
5
.
8
–
2
0
7
5
.
3
)
 
2
3
9
 
(
1
0
%
)
1
6
8
1
.
4
 
 
(
1
2
4
3
.
9
–
2
0
7
2
.
4
)
4
4
 
(
1
1
%
)
1
3
9
9
.
6
 
 
(
9
6
4
.
5
–
2
0
2
7
.
2
)
9
1
 
(
2
0
%
)
1
5
0
4
.
2
 
 
(
1
1
3
9
.
9
–
1
8
4
3
.
1
)
4
0
 
(
1
3
%
)
1
0
2
1
.
4
 
 
(
5
5
6
.
6
–
1
6
2
9
.
9
)
5
6
 
(
1
1
%
)
1
5
2
2
.
6
 
 
(
8
3
2
.
2
–
1
9
7
1
.
0
)
6
3
 
(
1
4
%
)
1
7
8
7
.
7
 
 
(
1
3
3
8
.
9
–
2
1
5
1
.
2
)
4
9
 
(
1
1
%
)
1
8
4
7
.
1
 
 
(
1
3
8
1
.
4
–
2
2
6
4
.
6
)
*
 
B
R
H
S
 
=
 
B
r
i
t
i
s
h
 
R
e
g
i
o
n
a
l
 
H
e
a
r
t
 
S
t
u
d
y
;
 
B
W
H
H
S
 
=
 
B
r
i
t
i
s
h
 
W
o
m
e
n
’
s
 
H
e
a
r
t
 
a
n
d
 
H
e
a
l
t
h
 
S
t
u
d
y
;
 
E
P
I
C
 
=
 
E
u
r
o
p
e
a
n
 
P
r
o
s
p
e
c
t
i
v
e
 
I
n
v
e
s
t
i
g
a
t
i
o
n
 
i
n
t
o
 
C
a
n
c
e
r
 
a
n
d
 
N
u
t
r
i
t
i
o
n
;
 
I
Q
R
 
=
 
i
n
t
e
r
q
u
a
r
t
i
l
e
 
r
a
n
g
e
 
b
e
t
w
e
e
n
 
2
5
t
h
 
a
n
d
 
7
5
t
h
 
p
e
r
c
e
n
t
i
l
e
;
 
P
i
P
 
=
 
P
a
t
c
h
 
i
n
 
P
r
a
c
t
i
c
e
.
 
T
y
p
i
c
a
l
 
c
o
t
i
n
i
n
e
 
v
a
l
u
e
s
 
(
n
e
v
e
r
 
s
m
o
k
e
r
s
 
a
n
d
 
f
o
r
m
e
r
 
s
m
o
k
e
r
s
 
a
p
p
r
o
x
i
m
a
t
e
l
y
 
5
 
n
m
o
l
/
L
;
 
c
u
r
r
e
n
t
 
s
m
o
k
e
r
s
 
>
8
5
 
n
m
o
l
/
L
)
 
(
4
7
)
.
 
N
u
m
b
e
r
 
o
f
 
r
i
s
k
 
a
l
l
e
l
e
s
 
e
x
p
r
e
s
s
e
d
 
a
s
 
z
e
r
o
,
 
o
n
e
,
 
o
r
 
t
w
o
 
c
o
p
i
e
s
 
o
f
 
t
h
e
 
r
s
1
0
5
1
7
3
0
 
T
 
a
l
l
e
l
e
 
o
r
 
r
s
1
6
9
6
9
9
6
8
 
A
 
a
l
l
e
l
e
.
‡
 
C
o
t
i
n
i
n
e
 
l
e
v
e
l
s
 
a
n
d
 
s
e
l
f
-
r
e
p
o
r
t
e
d
 
c
i
g
a
r
e
t
t
e
 
c
o
n
s
u
m
p
t
i
o
n
 
d
i
f
f
e
r
e
d
 
i
n
 
c
u
r
r
e
n
t
 
s
m
o
k
e
r
 
c
a
s
e
 
s
u
b
j
e
c
t
s
 
(
E
P
I
C
 
C
a
s
e
)
 
a
n
d
 
c
o
n
t
r
o
l
 
s
u
b
j
e
c
t
s
 
(
E
P
I
C
 
C
o
n
t
r
o
l
)
.
 
C
o
t
i
n
i
n
e
 
l
e
v
e
l
s
 
w
e
r
e
 
h
i
g
h
e
r
 
i
n
 
t
h
e
 
E
P
I
C
 
C
a
s
e
 
s
u
b
s
a
m
p
l
e
 
(
m
e
a
n
 
l
e
v
e
l
 
=
 
1
3
9
1
 
n
m
o
l
/
L
,
 
S
D
 
=
 
5
8
8
)
 
t
h
a
n
 
t
h
e
 
E
P
I
C
 
C
o
n
t
r
o
l
 
s
u
b
s
a
m
p
l
e
 
(
m
e
a
n
 
l
e
v
e
l
 
=
 
1
0
0
6
 
n
m
o
l
/
L
,
 
S
D
 
=
 
5
8
9
)
 
e
v
e
n
 
a
f
t
e
r
 
a
d
j
u
s
t
m
e
n
t
 
f
o
r
 
c
i
g
a
r
e
t
t
e
 
c
o
n
s
u
m
p
t
i
o
n
 
(
t
w
o
-
s
i
d
e
d
 
K
r
u
s
k
a
l
–
W
a
l
l
i
s
 
P
 
<
 
.
0
0
1
)
,
 
i
n
d
i
c
a
t
i
n
g
 
p
o
s
s
i
b
l
e
 
d
i
f
f
e
r
e
n
c
e
s
 
i
n
 
s
m
o
k
i
n
g
 
b
e
h
a
v
i
o
r
 
(
e
g
,
 
d
e
p
t
h
 
o
f
 
i
n
h
a
l
a
t
i
o
n
)
.
 
T
h
i
s
 
d
i
f
f
e
r
e
n
c
e
 
a
t
 
b
a
s
e
l
i
n
e
 
m
a
y
 
h
a
v
e
 
c
o
n
t
r
i
b
u
t
e
d
 
t
o
 
t
h
e
 
l
i
k
e
l
i
h
o
o
d
 
o
f
 
a
 
s
u
b
s
e
q
u
e
n
t
 
l
u
n
g
 
c
a
n
c
e
r
 
d
i
a
g
n
o
s
i
s
.
 
T
h
e
r
e
f
o
r
e
,
 
t
h
e
 
E
P
I
C
 
c
a
s
e
 
s
u
b
j
e
c
t
s
 
a
n
d
 
c
o
n
t
r
o
l
 
s
u
b
j
e
c
t
s
 
w
e
r
e
 
a
n
a
l
y
z
e
d
 
a
n
d
 
p
r
e
s
e
n
t
e
d
 
s
e
p
a
r
a
t
e
l
y
 
i
n
 
t
h
i
s
 
s
t
u
d
y
.jnci.oxfordjournals.org    JNCI | Review 745
lung cancer risk. Our estimate of the association between genotype 
and lung cancer risk was consistent with previously reported esti-
mates, even though we were only able to capture point prevalence 
smoking intensity (ie, based on current smoking only), and not 
lifetime  exposure.  These  data  therefore  support  the  conclusion 
that  association  of  rs1051730–rs16969968  genotype  with  lung 
cancer risk is mediated largely, if not wholly, via tobacco exposure. 
Although some studies have suggested a direct contribution of 
rs1051730–rs16969968  genotype  to  lung  carcinogenesis,  these 
have typically relied on self-report measures of smoking behavior 
which, as we have shown, do not fully capture actual exposure.
The association between these variants and lung cancer consti-
tutes Mendelian randomization evidence on the causal nature of 
the smoking–lung cancer association (48). In this case, we do not, 
of course, require such confirmation, but it serves as proof of principle 
for this approach. These findings also have important implications 
for epidemiology and genetic association studies, including large   
GWAS  of  cigarette  smoking  behavior,  which  typically  rely  on 
retrospective self-report measures. We discuss these implications 
below.
It is now well established that smokers modify their smoking 
behavior to self-titrate circulating nicotine to a level appropriate to 
their need (49). This compensatory behavior is achieved through 
varying the number of puffs, puff volume and interpuff interval, 
and covering the cigarette filter to reduce ventilation by sidestream 
air.  This  plasticity  of  smoking  behavior  means  that  estimating 
exposure to nicotine and tar in cigarette smokers is not possible 
through the use of machine protocols to calculate yield estimates 
(50) or through the simple counting of number and strength of 
cigarettes smoked. Smokers are able to titrate not only how many 
cigarettes they smoke but what strength of cigarette they smoke 
and how they smoke them. Therefore, either biochemical measures 
of exposure or naturalistic measures of smoking topography are 
necessary if an acceptable level of measurement precision is to be 
achieved (51).
By extension, GWAS that rely on self-report measures to quantify 
smoking behavior, and therefore tobacco exposure, may be insensitive 
to relatively modest genetic associations. Recent studies of smoking 
phenotypes have enjoyed considerable success in identifying loci 
associated with various aspects of smoking behavior (9,20,22). Our 
results suggest that these studies may have underestimated the 
magnitude of these associations (perhaps, in particular, in the 
case of heaviness of smoking phenotypes). It is also likely that a 
number of common variants that contribute an important pro-
portion of phenotypic variance may remain unidentified. Using 
biomarker phenotypes, such as cotinine, to assay nicotine con-
sumption  and  tobacco  exposure  may  improve  the  success  of   
GWAS and identify additional novel variants associated with 
nicotine consumption.
Our power analysis also indicates that these results have impor-
tant implications for the conduct of GWAS with respect to sample 
size. Considerably, smaller sample sizes may be sufficient to detect 
robust  genome-wide  associations  if  these  use  better  outcome 
measures—there is a trade-off between sample size and phenotype 
Figure  1.  Meta-analysis  of  association  of 
rs1051730–rs16969968 risk allele with ciga-
rette consumption in current smokers. Data 
from six independent studies contributed to 
the meta-analysis. Cotinine levels and self-
reported  cigarette  consumption  differed  in 
current  smoker  case  subjects  (EPIC  Case) 
and control subjects (EPIC Control) in the EPIC 
study, so they were analyzed separately. In 
each  study,  linear  regression  was  used  to 
calculate per-allele association of rs1051730–
rs16969968  genotype  with  daily  cigarette 
consumption. Units represent cigarettes per 
day. Unadjusted and adjusted (for cotinine 
levels) analyses are shown. The I
2 statistic was 
used  to  estimate  the  percentage  of  total 
variation in study estimates resulting from 
between-study heterogeneity. Individual study 
regression coefficients were combined using 
random effects methods. Squares represent 
per-allele regression coefficients, which rep-
resent mean increase in number of cigarettes 
per day per allele; size of the square repre-
sents inverse of the variance of the regres-
sion  coefficient;  horizontal  lines  represent 
95% CIs; diamonds represent summary esti-
mate combining the study-specific estimates 
using a random effects model; solid vertical 
line represents a regression coefficient of 0. 
P  for  heterogeneity  was  derived  from  the 
Cochran Q test (one-sided). All other statis-
tical  tests  were  two-sided,  and  statistical 
significance  required  a  P  value  of  .05  or 
less. BRHS = British Regional Heart Study; 
BWHHS = British Women’s Heart and Health 
Study;  CI  =  confidence  interval;  EPIC  = 
European  Prospective  Investigation  into 
Cancer and Nutrition; PiP = Patch in Practice.746   Review | JNCI  Vol. 104, Issue 10  |  May 16, 2012
quality and/or precision. It may not always be practical or finan-
cially  possible  to  collect  such  phenotypes  in  large  samples.  An 
initial GWAS based on a preliminary phenotype, which is easy to 
collect  (such  as  cigarette  consumption),  can  be  followed  up  by   
high-quality/precision  phenotyping  (such  as  cotinine  measure-
ments)  in  a  sample  selected  by  genotype  on  which  the  stored   
biological specimens are available. This combination could lead   
to  considerable  increases  in  statistical  power  and  efficiency.  In 
conventional  observational  epidemiology,  where  associations 
between self-reported smoking behavior and outcomes underesti-
mate  the  actual  etiological  associations  that  exist  (52),  more 
detailed phenotyping reveals stronger associations (46). Residual 
associations  between  other  exposures  and  smoking-related  out-
comes, such as lung cancer, which persist after statistical control 
for self-reported cigarette consumption, should therefore be treated 
with caution (53).
There are some limitations to consider when interpreting these 
results. First, our data are drawn from disparate studies recruited 
from various populations. Nevertheless, the consistency in effect 
size estimates across samples, and the lack of substantial between-
study heterogeneity, suggests that the impact of this is minimal. 
Second, our estimate of the strength of the association between 
genotype and cotinine exposure on lung cancer risk relies on an 
indirect comparison with published data. Moreover, it relies on 
measures of current smoking rather than lifetime exposure, which 
is more strongly associated with lung cancer risk. Nevertheless, the 
triangulation of our data with published estimates of the association 
of genotype with lung cancer risk raises confidence in these results. 
Third, we lacked repeated measurement of cotinine, which would 
allow  the  assessment  of  within-  and  between-person  variation   
(eg,  due  time  between  last  cigarette  smoked  and  collection  of   
biological sample for cotinine analysis), and the time of day that 
cotinine  samples  were  collected  was  not  standardized,  either 
within or between samples. However, the relatively long half-life 
of cotinine means it provides a reasonably stable measure of expo-
sure  in  regular  cigarette  smokers.  Also,  the  lack  of  substantial 
between-study  heterogeneity  again  suggests  that  the  impact  of 
this was modest. Fourth, we were unable to capture interindi-
vidual  variation  in  cotinine  metabolism,  for  example  due  to   
genetic variation within cytochrome P450, family 2, subfamily A, 
polypeptide  6  (CYP2A6),  which  encodes  the  CYP2A6  enzyme 
primarily responsible for the metabolism of nicotine to cotinine 
(54). Therefore, although cotinine levels provide a considerably 
more  precise  measure  of  tobacco  exposure  than  self-report 
measures, including measures of CYP2A6 activity might serve to 
refine this further. It is also possible that increased nicotine con-
sumption among rs1051730–rs16969968 risk allele carriers may 
result in CYP2A6 enzyme induction, giving rise to a positive feed-
back  cycle  as  faster  metabolism  of  nicotine  leads  to  increased 
consumption to maintain circulating levels (55). However, evi-
dence suggests that nicotine metabolism is inhibited in smokers 
compared with nonsmokers (56). We also did not adjust for other 
factors known to influence nicotine metabolism, such as sex and 
body mass index.
Figure  2.  Meta-analysis  of  association  of 
rs1051730–rs16969968  risk  allele  with  coti-
nine levels in current smokers. Data from six 
independent  studies  contributed  to  the 
meta-analysis.  Cotinine  levels  and  self-
reported  cigarette  consumption  differed  in 
current  smoker  case  subjects  (EPIC  Case) 
and  control  subjects  (EPIC  Control)  in  the 
EPIC  study,  so  they  were  analyzed  sepa-
rately.  In  each  study,  linear  regression   
was used to calculate per-allele association 
of  rs1051730–rs16969968  genotype  with 
cotinine  levels.  Units  represent  nmol/L. 
Unadjusted and adjusted (for cigarette con-
sumption) analyses are shown. The I
2 statis-
tic was used to estimate the percentage of 
total  variation  in  study  estimates  resulting 
from  between-study  heterogeneity. 
Individual study regression coefficients were 
combined  using  random  effects  methods. 
Squares represent per allele regression coef-
ficient,  which  represents  mean  increase  in 
cotinine levels per allele; size of the square 
represents  inverse  of  the  variance  of  the   
regression coefficient; horizontal lines repre-
sent 95% CIs; diamonds represent summary 
estimate  combining  the  study-specific  esti-
mates  with  a  random  effects  model;  solid 
vertical line represents a regression coeffi-
cient of 0. P for heterogeneity was derived 
from  the  Cochran  Q  test  (one-sided).  All 
other  statistical  tests  were  two-sided,  and 
statistical significance required a P value of 
.05  or  less.  BRHS  =  British  Regional  Heart 
Study; BWHHS = British Women’s Heart and 
Health Study; CI = confidence interval; EPIC = 
European  Prospective  Investigation  into 
Cancer and Nutrition; PiP = Patch in Practice.jnci.oxfordjournals.org    JNCI | Review 747
In  conclusion,  our  data  indicate  that  much  of  the  debate   
regarding  whether  the  association  of  rs1051730–rs16969968   
genotype  with  lung  cancer  is  direct  or  operate  indirectly  via   
tobacco exposure is essentially due to imprecision in the measures 
of tobacco use and exposure used in most studies. More impor-
tantly, our results show that the search for even larger sample sizes 
in  GWAS  may  generate  diminishing  returns  if  this  is  at  the 
expense of phenotype precision. The use of objective measures of 
smoking behavior in genome-wide studies may reveal novel vari-
ants associated with these outcomes, which would be undetectable 
using conventional self-report measures.
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